爪真菌症治療の世界市場レポート 2024年

爪真菌症治療市場規模は近年力強く成長しています。2023年の33億9,000万米ドルから2024年には36億5,000万米ドルに、CAGR7.5％で成長します。実績期間の成長は、真菌感染症の増加、人口の高齢化、社会的認識、爪水虫の有病率の上昇、可処分所得の上昇に起因しています。

爪真菌症治療市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR6.7％で47億3,000万米ドルに成長します。予測期間の成長は、高齢化、遠隔医療の拡大、併用療法、ヘルスケアへのアクセスの増加、ライフスタイルや環境要因の変化、糖尿病有病率の増加などに起因すると考えられます。予測期間における主な動向としては、皮膚科学的進歩、ドラッグデリバリーの革新、個別化治療計画、局所治療の進歩、デジタルヘルスソリューション、レーザー治療などが挙げられます。

真菌感染症の有病率の増加は、当面の爪真菌症治療市場の拡大を牽引する見通しです。真菌感染症は、さまざまな真菌によって引き起こされる微生物疾患のスペクトルを包含し、身体のさまざまな部位に影響を及ぼしたり、特定の健康状態を引き起こしたりします。爪真菌症は真菌による爪の感染症であり、従来は抗真菌剤の内服や抗真菌剤の外用により、根本的な真菌感染を根絶し、健康な爪の成長の回復を促していました。例えば、2023年3月に米国疾病予防管理センター（CDC）が発表した最近のデータでは、2021年の米国におけるC. aurisの臨床症例数は3,270例、スクリーニング症例数は7,413例でした。さらに、CDCは真菌感染症による死亡者数の増加を報告しており、2020年の5,922人から2021年には7,199人に増加しています。その結果、真菌感染症の急増が爪真菌症治療市場の成長促進要因となっています。

2023年の爪真菌症治療市場では北米が最大地域でした。アジア太平洋は予測期間中に最も急成長する地域と予想されます。爪真菌症治療レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の爪真菌症治療市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 遠位爪甲下爪真菌症
• 白色表在性爪真菌症
• 近位爪甲下爪真菌症
• カンジダ性爪真菌症
• その他のタイプ
• 世界の爪真菌症治療市場、治療タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 薬物
• レーザー治療
• 光線力学療法
• 世界の爪真菌症治療市場、年齢層別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 0歳～18歳
• 18歳～39歳
• 40歳～64歳
• 65歳以上
• 世界の爪真菌症治療市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• その他の流通チャネル

第7章 地域および国の分析

• 世界の爪真菌症治療市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の爪真菌症治療市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 爪真菌症治療市場の競合情勢
• 爪真菌症治療市場の企業プロファイル
  • Johnson &Johnson Services Inc.
  • Bristol-Myers Squibb Company
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Hetero Drugs Ltd.

第31章 その他の主要および革新的な企業

• Sun Pharmaceutical Industries Limited
• Cadila Pharmaceuticals Ltd.
• Dr. Reddys Laboratories Ltd.
• Intas Pharmaceuticals Limited
• Cipla Limited
• Lupin Limited
• Glenmark Pharmaceuticals Ltd.
• Aurobindo Pharma Limited
• Alkem Laboratories Limited
• Jubilant Life Sciences Ltd.
• Torrent Pharmaceuticals Ltd.
• Mankind Pharma Ltd.
• Biocon Limited
• Emcure Pharmaceuticals Limited
• Alembic Pharmaceuticals Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Onychomycosis Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on onychomycosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for onychomycosis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The onychomycosis treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Distal Sublingual Onychomycosis; White Superficial Onychomycosis; Proximal Sublingual Onychomycosis; Candida Onychomycosis; Other Types
• 2) By Treatment Type: Drugs; Laser Therapy; Photodynamic Therapy
• 3) By Age Group: 0 To 18 Years; 18 To 39 Years; 40 To 64 Years; 65 Years And Above
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• Companies Mentioned: Johnson & Johnson Services Inc.; Bristol-Myers Squibb Company; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Hetero Drugs Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Onychomycosis treatment involves medical interventions and strategies employed to address and cure onychomycosis, a fungal infection that impacts both fingernails and toenails. The management of onychomycosis typically comprises a combination of topical and oral antifungal medications, along with preventive measures aimed at reducing the risk of recurrence.

The primary forms of onychomycosis include distal sublingual onychomycosis, white superficial onychomycosis, proximal sublingual onychomycosis, candida onychomycosis, and others. Distal sublingual onychomycosis, for instance, is a fungal nail infection that affects the underside of the nail tip, often caused by dermatophyte fungi. Treatments encompass a variety of approaches, including medications, laser therapy, and photodynamic therapy, catering to different age groups, including individuals aged 0 to 18 years, 18 to 39 years, 40 to 64 years, and those aged 65 years and above. Multiple distribution channels are involved, including hospital pharmacies, retail pharmacies, and others.

The onychomycosis treatment market research report is one of a series of new reports from The Business Research Company that provides onychomycosis treatment market statistics, including onychomycosis treatment industry global market size, regional shares, competitors with a onychomycosis treatment market share, detailed onychomycosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the onychomycosis treatment industry. This onychomycosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The onychomycosis treatment market size has grown strongly in recent years. It will grow from $3.39 billion in 2023 to $3.65 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing fungal infections, aging population, public awareness, rising prevalence of onychomycosis, rising disposable incomes

.

The onychomycosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.73 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to aging population, telemedicine expansion, combination therapies, increasing access to healthcare, changing lifestyles and environmental factors, increasing prevalence of diabetes. Major trends in the forecast period include dermatological advancements, drug delivery innovations, personalized treatment plans, topical treatment advances, digital health solutions, laser therapy.

The increasing prevalence of fungal infections is poised to drive the expansion of the onychomycosis treatment market in the foreseeable future. Fungal infections encompass a spectrum of microbial diseases caused by a variety of fungi, affecting diverse areas of the body or triggering specific health conditions. Onychomycosis, a fungal nail infection, is conventionally managed with oral antifungal drugs or topical antifungal solutions to eradicate the underlying fungal infection and promote the restoration of healthy nail growth. For example, recent data from the Centers for Disease Control and Prevention (CDC) in March 2023 revealed 3,270 clinical cases and 7,413 screening cases of C. auris in the United States in 2021. Additionally, the CDC reported an increase in the total number of deaths resulting from fungal infections, rising from 5,922 in 2020 to 7,199 in 2021. Consequently, the surge in fungal infections is a key driver of growth in the onychomycosis treatment market.

The rising prevalence of diabetes is poised to drive the growth of the onychomycosis treatment market in the foreseeable future. Diabetes is a chronic medical condition characterized by elevated levels of blood glucose (blood sugar), increasing the likelihood of developing onychomycosis, elevating the risk of infection, and delaying the healing process. Topical and laser therapies play a crucial role in preventing complications and enhancing foot health, ultimately reducing the risk of subsequent infections. For example, in March 2021, a report from the LSU AgCenter, a Louisiana-based agricultural research center, indicated that in 2021, the United States had over 34.2 million individuals living with diabetes, and it is projected that the global population affected by diabetes will surge to 578 million by the year 2030. As a result, the growing prevalence of diabetes is a key driver behind the expansion of the onychomycosis treatment market.

The primary challenge, and one that could impede the market's growth during the forecast period, is the restricted availability of approved treatments. Currently, the treatments for onychomycosis, including topical and oral antifungal medications, exhibit limited effectiveness and may necessitate a prolonged duration to deliver visible results. Moreover, not all available therapies have received approval for use in all regions, and the process of obtaining regulatory approval for novel treatments can be protracted and costly. For example, although ciclopirox 8% hydrolacquer and polyurethanes have exhibited promise in clinical trials, their widespread availability and approval for use in all countries have yet to be achieved. Consequently, the onychomycosis treatment market is constrained by the limited availability of approved treatments.

Prominent companies operating in the onychomycosis treatment market are placing a strong emphasis on the development of novel products, like MOB-015, and obtaining approvals from regulatory agencies as part of their strategy to secure a competitive edge within the market. For instance, Moberg Pharma AB, a pharmaceutical company based in Sweden, which successfully obtained approval for MOB-015 from the European Union to treat mild to moderate fungal nail infections in adults. This EU approval marks a significant milestone as the first global marketing authorization for this innovative onychomycosis medication. The approval is underpinned by two Phase 3 trials supporting MOB-015, which demonstrated enhanced mycological cure rates (76% compared to up to 42% for comparators) and a substantially higher overall cure rate than the vehicle, all achieved without any occurrence of serious adverse effects. MOB-015, a topical terbinafine formulation, enables the delivery of effective terbinafine concentrations to the nail and nail bed without the associated systemic exposure risk associated with oral terbinafine treatments.

In August 2023, Karo Healthcare AB, a Swedish consumer healthcare company, completed the acquisition of Lamisil from Haleon PLC for an approximate sum of $297.86 million. This strategic move to acquire Lamisil significantly enriches Karo Healthcare's portfolio of over-the-counter (OTC) products and extends its offerings within the field of foot health. Furthermore, this transaction serves to broaden Karo's global footprint and augment its market presence in the realm of Foot Health. Lamisil, a well-known oral antifungal medication primarily utilized for the treatment of onychomycosis, was previously held by Haleon PLC, a UK-based consumer healthcare enterprise.

Major players in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

North America was the largest region in the onychomycosis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the onychomycosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The onychomycosis treatment market consists of revenues earned by entities by providing combination therapy, nail debridement and Carbon dioxide ablative laser treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The onychomycosis treatment market also includes sales of griseofulvin, terbinafine, itraconazole, ketoconazole and more. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Onychomycosis Treatment Market Characteristics

3. Onychomycosis Treatment Market Trends And Strategies

4. Onychomycosis Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Onychomycosis Treatment Market Size and Growth

• 5.1. Global Onychomycosis Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Onychomycosis Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Onychomycosis Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Onychomycosis Treatment Market Segmentation

• 6.1. Global Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Distal Sublingual Onychomycosis
• White Superficial Onychomycosis
• Proximal Sublingual Onychomycosis
• Candida Onychomycosis
• Other Types
• 6.2. Global Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Drugs
• Laser Therapy
• Photodynamic Therapy
• 6.3. Global Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

0 To 18 Years

18 To 39 Years

40 To 64 Years

65 Years And Above

• 6.4. Global Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels

7. Onychomycosis Treatment Market Regional And Country Analysis

• 7.1. Global Onychomycosis Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Onychomycosis Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Onychomycosis Treatment Market

• 8.1. Asia-Pacific Onychomycosis Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Onychomycosis Treatment Market

• 9.1. China Onychomycosis Treatment Market Overview
• 9.2. China Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Onychomycosis Treatment Market

• 10.1. India Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Onychomycosis Treatment Market

• 11.1. Japan Onychomycosis Treatment Market Overview
• 11.2. Japan Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Onychomycosis Treatment Market

• 12.1. Australia Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Onychomycosis Treatment Market

• 13.1. Indonesia Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Onychomycosis Treatment Market

• 14.1. South Korea Onychomycosis Treatment Market Overview
• 14.2. South Korea Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Onychomycosis Treatment Market

• 15.1. Western Europe Onychomycosis Treatment Market Overview
• 15.2. Western Europe Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Onychomycosis Treatment Market

• 16.1. UK Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Onychomycosis Treatment Market

• 17.1. Germany Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Onychomycosis Treatment Market

• 18.1. France Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Onychomycosis Treatment Market

• 19.1. Italy Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Onychomycosis Treatment Market

• 20.1. Spain Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Onychomycosis Treatment Market

• 21.1. Eastern Europe Onychomycosis Treatment Market Overview
• 21.2. Eastern Europe Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Onychomycosis Treatment Market

• 22.1. Russia Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Onychomycosis Treatment Market

• 23.1. North America Onychomycosis Treatment Market Overview
• 23.2. North America Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Onychomycosis Treatment Market

• 24.1. USA Onychomycosis Treatment Market Overview
• 24.2. USA Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Onychomycosis Treatment Market

• 25.1. Canada Onychomycosis Treatment Market Overview
• 25.2. Canada Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Onychomycosis Treatment Market

• 26.1. South America Onychomycosis Treatment Market Overview
• 26.2. South America Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Onychomycosis Treatment Market

• 27.1. Brazil Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Onychomycosis Treatment Market

• 28.1. Middle East Onychomycosis Treatment Market Overview
• 28.2. Middle East Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Onychomycosis Treatment Market

• 29.1. Africa Onychomycosis Treatment Market Overview
• 29.2. Africa Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Onychomycosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Onychomycosis Treatment Market Competitive Landscape
• 30.2. Onychomycosis Treatment Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Bristol-Myers Squibb Company
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Viatris Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Teva Pharmaceutical Industries Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Hetero Drugs Ltd.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Onychomycosis Treatment Market Other Major And Innovative Companies

• 31.1. Sun Pharmaceutical Industries Limited
• 31.2. Cadila Pharmaceuticals Ltd.
• 31.3. Dr. Reddys Laboratories Ltd.
• 31.4. Intas Pharmaceuticals Limited
• 31.5. Cipla Limited
• 31.6. Lupin Limited
• 31.7. Glenmark Pharmaceuticals Ltd.
• 31.8. Aurobindo Pharma Limited
• 31.9. Alkem Laboratories Limited
• 31.10. Jubilant Life Sciences Ltd.
• 31.11. Torrent Pharmaceuticals Ltd.
• 31.12. Mankind Pharma Ltd.
• 31.13. Biocon Limited
• 31.14. Emcure Pharmaceuticals Limited
• 31.15. Alembic Pharmaceuticals Ltd.

32. Global Onychomycosis Treatment Market Competitive Benchmarking

33. Global Onychomycosis Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Onychomycosis Treatment Market

35. Onychomycosis Treatment Market Future Outlook and Potential Analysis

• 35.1 Onychomycosis Treatment Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Onychomycosis Treatment Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Onychomycosis Treatment Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer